Have a personal or library account? Click to login
Outcomes of patients with Acute Myeloid Leukemia receiving venetoclax in combination with azacitidine: A single center retrospective study from Pakistan Cover

Outcomes of patients with Acute Myeloid Leukemia receiving venetoclax in combination with azacitidine: A single center retrospective study from Pakistan

Open Access
|May 2025

Figures & Tables

Figure 1.

The proportion of different types of mutations observed in the patients.
The proportion of different types of mutations observed in the patients.

Figure 2.

Kaplan Meier Curve for overall survival among patients with Acute Myeloid Leukemia treated with Venetoclax and Azacitidine.
Kaplan Meier Curve for overall survival among patients with Acute Myeloid Leukemia treated with Venetoclax and Azacitidine.

Figure 3.

Kaplan Meier curves for overall survival among patients with AML stratified by gender.
Kaplan Meier curves for overall survival among patients with AML stratified by gender.

Figure 4.

Kaplan Meier curves for overall survival among patients with AML stratified by comorbid status.
Kaplan Meier curves for overall survival among patients with AML stratified by comorbid status.

Multivariable cox-regression model for predictors of survival in our cohort

VariableHazard Ratio95% Confidence Intervalp value
Age1.03[0.99 – 1.08]0.15
Number of cycles0.74[0.61 – 0.87]< 0.01
White cell counts at presentation1.00[0.99 – 1.01]0.89
Presence of cytogenetic abnormalities*0.82[0.40 – 1.71]0.60
Presence of molecular abnormalities*0.73[0.27 – 2.02]0.55

Molecular abnormalities identified in our cohort

Molecular abnormalitiesCount
FLT 3-ITD7
NPM 14
Others (CALR, U2AF1, KRAS, PHF6)4
IDH-1/23
TP532
WT-12
NRAS2
TET-22
RUNX-12
JAK22
ASXL-11

Patient characteristics_

Variablen (%) or mean ± SD
Gender
Male45 (77.6)
Female13 (22.4)
Age61.5 [55.0 – 67.0]
Number of cycles4 [2 – 6]
White cell counts at presentation5.8 [2.4 – 16.1]
Outcome
Death44 (75.9)
Under treatment9 (15.5)
Palliative care1 (1.7)
Lost to follow up4 (6.9)
Secondary leukemia
MDS transformation7 (12.1)
CMML transformation2 (3.4)
MF transformation2 (3.4)
Remission achieved
Yes22 (37.9)
No33 (56.9)
Not known3 (5.2)
Cause of death
Refractory disease30 (63.8)
Relapsed disease10 (21.3)
Secondary Cause*4 (8.5)
Not Known3 (6.4)
Comorbid conditions
Hypertension17 (29.3)
Diabetes Mellitus20 (34.5)
Coronary Artery Disease4 (6.9)

Cytogenetic abnormalities identified in our cohort

Cytogenetic abnormalitiesn (%)
Normal20 (34)
Complex karyotypic abnormalities*5 (9)
Deletion 7q4 (7)
Translocation 8:212 (3)
Trisomy 82 (3)
Monosomy X2 (3)
Deletion 11q1 (2)
Inversion 161 (2)
Translocation 1:221 (2)
Trisomy 111 (2)
Trisomy 191 (2)
Metaphysis not found18 (31)
Language: English
Page range: 1 - 7
Published on: May 29, 2025
Published by: Shakuat Khanum Memorial Cancer Hospital and Research Centre
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2025 Junaid Alam, Lavita Kumari, Usman Shaikh, Akbar Khan Muhammad Ali, published by Shakuat Khanum Memorial Cancer Hospital and Research Centre
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.